What does Zomagen Biosciences Belgium do?

Zomagen Biosciences Belgium is a research organisation in Gent. Private Limited, started on 27 February 2020, 1 establishment.

What is the address of Zomagen Biosciences Belgium?

The registered office of Zomagen Biosciences Belgium is located at Technologiepark-Zwijnaarde 94, 9052 Gent.

Is Zomagen Biosciences Belgium still active?

Yes. According to the CBE (29 October 2026) Zomagen Biosciences Belgium is active, legal situation “Normale toestand”, started on 27 February 2020.

Is Zomagen Biosciences Belgium registered on Peppol?

Yes, Zomagen Biosciences Belgium is registered on the Peppol network with ID 0208:0744519837.

What is the enterprise number of Zomagen Biosciences Belgium?

The enterprise number of Zomagen Biosciences Belgium is BE0744519837.

When was Zomagen Biosciences Belgium founded?

Zomagen Biosciences Belgium was founded on 27 February 2020.

Who are the directors of Zomagen Biosciences Belgium?

According to the 2025 annual accounts, the directors of Zomagen Biosciences Belgium are: Raju Mohan.

Is Zomagen Biosciences Belgium a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 February 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Zomagen Biosciences Belgium make in 2025?

Zomagen Biosciences Belgium posted a profit after taxes of € 87,406 in financial year 2025.

What is the revenue of Zomagen Biosciences Belgium?

As a small company, Zomagen Biosciences Belgium is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,165,956.

How much does an employee at Zomagen Biosciences Belgium earn?

The average wage cost per full-time employee at Zomagen Biosciences Belgium was € 159,600 in 2025: staff costs of € 989,255 for 6.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Zomagen Biosciences Belgium have?

According to the 2025 annual accounts, Zomagen Biosciences Belgium has 6.2 full-time equivalents (FTE).

Zomagen Biosciences Belgium (Private Limited) - Gent

Dossier Zomagen Biosciences Belgium, printed on 29 October 2026 from databakkes.be/en/0744519837/zomagen-biosciences-belgium. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Zomagen Biosciences Belgium from Gent, company number BE0744519837, closed financial year 2025 with a result of € 87,406 after tax. For that financial year Zomagen Biosciences Belgium recorded a gross margin of € 1.2 million and equity of € 467,552. Compared with financial year 2024, the result moved from € 85,874 to € 87,406. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Growing

€ 467,552

▲ 23% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 87,406

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 157,782

▲ 293% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 387,552.

People and assets in 2025

Full-time equivalents

6.2

▲ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 989,255

▲ 30% vs 2024

€ 159,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,677

▲ 7% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 71,452

▲ 24% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 136,930

▲ 6% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 546,567 Gross margin 2022: € 546,567 First fiscal year in the series	€ 964,765 Gross margin 2023: € 964,765 ▲ 77% vs 2022 (€ 546,567) Favourable step	€ 910,856 Gross margin 2024: € 910,856 ▼ 6% vs 2023 (€ 964,765) Unfavourable step	€ 1,165,956 Gross margin 2025: € 1,165,956 ▲ 28% vs 2024 (€ 910,856) Favourable step	▲ 28%
Profit after taxes	€ 50,056 Profit after taxes 2022: € 50,056 First fiscal year in the series	€ 82,376 Profit after taxes 2023: € 82,376 ▲ 65% vs 2022 (€ 50,056) Favourable step	€ 85,874 Profit after taxes 2024: € 85,874 ▲ 4% vs 2023 (€ 82,376) Favourable step	€ 87,406 Profit after taxes 2025: € 87,406 ▲ 2% vs 2024 (€ 85,874) Favourable step	▲ 2%
Equity	€ 211,896 Equity 2022: € 211,896 First fiscal year in the series	€ 294,272 Equity 2023: € 294,272 ▲ 39% vs 2022 (€ 211,896) Favourable step	€ 380,146 Equity 2024: € 380,146 ▲ 29% vs 2023 (€ 294,272) Favourable step	€ 467,552 Equity 2025: € 467,552 ▲ 23% vs 2024 (€ 380,146) Favourable step	▲ 23%
Total debts	€ 2,127,495 Total debts 2022: € 2,127,495 First fiscal year in the series	€ 1,103,319 Total debts 2023: € 1,103,319 ▼ 48% vs 2022 (€ 2,127,495) Favourable step	€ 1,029,910 Total debts 2024: € 1,029,910 ▼ 7% vs 2023 (€ 1,103,319) Favourable step	€ 1,366,677 Total debts 2025: € 1,366,677 ▲ 33% vs 2024 (€ 1,029,910) Unfavourable step	▲ 33%
Cash	€ 417,813 Cash 2022: € 417,813 First fiscal year in the series	€ 102,386 Cash 2023: € 102,386 ▼ 75% vs 2022 (€ 417,813) Unfavourable step	€ 40,162 Cash 2024: € 40,162 ▼ 61% vs 2023 (€ 102,386) Unfavourable step	€ 157,782 Cash 2025: € 157,782 ▲ 293% vs 2024 (€ 40,162) Favourable step	▲ 293%
Retained profit	€ 131,896 Retained profit 2022: € 131,896 First fiscal year in the series	€ 214,272 Retained profit 2023: € 214,272 ▲ 62% vs 2022 (€ 131,896) Favourable step	€ 300,146 Retained profit 2024: € 300,146 ▲ 40% vs 2023 (€ 214,272) Favourable step	€ 387,552 Retained profit 2025: € 387,552 ▲ 29% vs 2024 (€ 300,146) Favourable step	▲ 29%
Balance sheet total	€ 2,339,391 Balance sheet total 2022: € 2,339,391 First fiscal year in the series	€ 1,397,591 Balance sheet total 2023: € 1,397,591 ▼ 40% vs 2022 (€ 2,339,391) Unchanged	€ 1,410,056 Balance sheet total 2024: € 1,410,056 ▲ 1% vs 2023 (€ 1,397,591) Unchanged	€ 1,834,229 Balance sheet total 2025: € 1,834,229 ▲ 30% vs 2024 (€ 1,410,056) Unchanged	▲ 30%
Employees (FTE)	3.9 Employees (FTE) 2022: 3.9 First fiscal year in the series	4.5 Employees (FTE) 2023: 4.5 ▲ 0.6 vs 2022 (3.9) Unchanged	5.5 Employees (FTE) 2024: 5.5 ▲ 1 vs 2023 (4.5) Unchanged	6.2 Employees (FTE) 2025: 6.2 ▲ 0.7 vs 2024 (5.5) Unchanged	▲ 0.7

Key figures of Zomagen Biosciences Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Zomagen Biosciences Belgium?

What happened at Zomagen Biosciences Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 6, 2026 New annual accounts for financial year 2025: profit of € 87,406 (▲ 2% vs 2024). Source: NBB ↗
Feb 27, 2020 New establishment in Gent. KBO
Feb 27, 2020 Start of the company according to the CBE. KBO

In short

From € 50,056 profit in 2022 to € 87,406 profit in 2025.

Paid € 110,857 in corporate taxes since 2022.

Best year ever: 2025, with € 87,406 profit.

On average € 188,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Raju Mohan

Zomagen Biosciences Belgium

Behind Zomagen Biosciences Belgium is Raju Mohan.

Directors

According to the 2025 annual accounts

Raju Mohan

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Technologiepark-Zwijnaarde 94

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

ILiAD Biotechnologies

€ 1.4 million gross margin · 2025

AnimAb

€ 28,596 gross margin · 2025

ExeVir Bio

€ -1.2 million gross margin · 2025

Protealis

€ 1.1 million gross margin · 2025

YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0744.519.837

VAT number

BE 0744.519.837

Registered office

Technologiepark-Zwijnaarde 94, 9052 Gent

Names & denominations

Zomagen Biosciences Belgium

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 February 2020

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige zakelijke dienstverlening, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

Zomagen Biosciences Belgium

Financials

What happened to Zomagen Biosciences Belgium?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions